• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Sepsis - Pipeline Review, H2 2012 Product Image

Sepsis - Pipeline Review, H2 2012

  • ID: 2298725
  • October 2012
  • 100 pages
  • Global Markets Direct

Sepsis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Sepsis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Sepsis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sepsis. Sepsis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Sepsis.
- A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Sepsis Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Sepsis 11
Sepsis Therapeutics under Development by Companies 13
Sepsis Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Sepsis Therapeutics – Products under Development by Companies 22
Sepsis Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Sepsis Therapeutics Development 24
Daiichi Sankyo Company, Ltd 24
Cephalon, Inc. 25
Chiesi Farmaceutici SpA 26
Chong Kun Dang Pharmaceutical 27
Eisai Co., Ltd. 28
Sirtris Pharmaceuticals, Inc. 29
Asahi Kasei Pharma 30
MSM Protein Technologies, Inc. 31
Viral Genetics, Inc. 32
NOXXON Pharma AG 33
Atox Bio Inc. 34
Biosynexus Incorporated 35
NexBio, Inc. 36
Endacea, Inc. 37
Aphoenix, Inc. 38
ISU ABXIS Co.,Ltd. 39
Faron Pharmaceuticals, Ltd. 40
Sepsis – Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 48
eritoran tetrasodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
thrombomodulin alfa - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
pagibaximab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NOX-D14 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
AFX-300 Series - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CKD-712 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Viradin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
cefazolin - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
hydrocortisone acetate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Piperacillin + Tazobactam - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cotrimoxazole - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
simvastatin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AB-103 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
pleconaril - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Procaine Penicillin + Gentamicin + Amoxicillin - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
daptomycin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
rosuvastatin calcium - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
clarithromycin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
CS-4771 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
J5-OMP Vaccine + CpG 7909 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Ticarcillin + Clavulanic Acid - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Chlorhexidine Gluconate - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
CaCP-29 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ketanserin - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SRT-2379 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Sepsicillin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Immuno-modulating peptides - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MSM-236 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
VGV-S - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
L-97-1 i.v. - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
AB-022 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
meropenem - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Heparin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Sepsis Therapeutics – Drug Profile Updates 88
Sepsis Therapeutics – Discontinued Products 90
Sepsis Therapeutics - Dormant Products 91
Sepsis – Product Development Milestones 92
Featured News & Press Releases 92
Feb 02, 2012: Agennix Halts Phase II/III OASIS Trial In Severe Sepsis 92
Jan 18, 2012: InflaRx Successfully Completes Clinical Phase I Trial With IFX-1 92
Oct 25, 2011: Lilly Announces Withdrawal Of Xigris Following Recent Clinical Trial Results 92
Aug 10, 2011: Agennix Receives European Patent Covering Use Of Talactoferrin To Treat Cancer 93
Jul 05, 2011: Agennix Announces Data From Talactoferrin Phase II Trial In Severe Sepsis Presented At World Conference On Lung Cancer 94
Jun 30, 2011: Agennix Initiates Phase II/III OASIS Trial With Talactoferrin In Severe Sepsis 94
Jun 05, 2011: Agennix Announces New Data From Talactoferrin Phase II Trials In Non-small Cell Lung Cancer And In Severe Sepsis Presented At ASCO Annual Meeting 95
Jun 01, 2011: Agennix Announces Talactoferrin Data To Be Presented At ASCO 2011 Annual Meeting 96
May 18, 2011: New Data From Agennix's Talactoferrin Phase II Trial In Severe Sepsis Presented At ATS International Conference 97
May 12, 2011: Atox Bio Completes Phase I clinical study Of AB103 For Severe Bacterial Infections And Sepsis 97
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100

List of Tables
Number of Products Under Development for Sepsis, H2 2012 11
Products under Development for Sepsis – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 23
Daiichi Sankyo Company, Ltd, H2 2012 24
Cephalon, Inc., H2 2012 25
Chiesi Farmaceutici SpA, H2 2012 26
Chong Kun Dang Pharmaceutical, H2 2012 27
Eisai Co., Ltd., H2 2012 28
Sirtris Pharmaceuticals, Inc., H2 2012 29
Asahi Kasei Pharma, H2 2012 30
MSM Protein Technologies, Inc., H2 2012 31
Viral Genetics, Inc., H2 2012 32
NOXXON Pharma AG, H2 2012 33
Atox Bio Inc., H2 2012 34
Biosynexus Incorporated, H2 2012 35
NexBio, Inc., H2 2012 36
Endacea, Inc., H2 2012 37
Aphoenix, Inc., H2 2012 38
ISU ABXIS Co.,Ltd., H2 2012 39
Faron Pharmaceuticals, Ltd., H2 2012 40
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Stage and Molecule Type, H2 2012 47
Sepsis Therapeutics – Drug Profile Updates 88
Sepsis Therapeutics – Discontinued Products 90
Sepsis Therapeutics – Dormant Products 91

List of Figures
Number of Products under Development for Sepsis, H2 2012 11
Products under Development for Sepsis – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 16
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Discovery and Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 41
Assessment by Combination Products, H2 2012 42
Assessment by Route of Administration, H2 2012 43
Assessment by Stage and Route of Administration, H2 2012 44
Assessment by Molecule Type, H2 2012 45
Assessment by Stage and Molecule Type, H2 2012 46

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos